As researchers embrace more complex cellular models, high-content analysis brings new opportunities and challenges to drug discovery.

The ISTAND program is designed to advance promising, high-impact New Approach Methodologies (NAMs) through structured FDA engagement to inform regulatory decision-making. Acceptance of Axion’s LOI ...

Welcome to the Weekly Rundown where the DDN editors cover this week’s top biotech and pharma news.

Salt Lake City, Utah, February 9, 2026 – Carterra Inc., the leading provider of technologies enabling high-throughput biology, today announced the launch of the Carterra Vega High-Throughput Surface ...

Twenty years ago, drug discovery ran on a simple script of screening compounds and hoping for a hit. This exclusive ebook, ...

A scientist who assumes there is one authoritative FDA AI drug development guidance document to read would be forgiven, and wrong. The reality is closer to a paper trail: a 2021 action plan that most ...

Alzheimer’s disease often overlaps with other causes of cognitive decline. A new proteomics project aims to untangle that ...

The biotechnology industry is moving past the initial excitement of artificial intelligence (AI) to confront a more complex reality: the transition from isolated digital tools to fully integrated, ...

Traditional animal models remain an important part of preclinical research, but species differences can limit translation of ...

Losing weight can happen via two paths: eating less, or spending more energy. Today’s blockbuster GLP-1 drugs are well-known for their ability to help people eat less, but finding drugs that increase ...

From AI agents to cell therapy to Alzheimer’s drug pipelines, this issue follows the same problem across three fields:what it takes to turn something that works once into something that works at scale ...

Priyom Bose earned her Ph.D. in Plant Biology and Biotechnology from the University of Madras, India, in 2019 before ...